Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Biotherapy
Published in: Biotherapy 4/1998

01-12-1998

Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice

Authors: Takusaburo Ebina, Yoshiaki Fujimiya

Published in: Biotherapy | Issue 4/1998

Login to get access
Metadata
Title
Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice
Authors
Takusaburo Ebina
Yoshiaki Fujimiya
Publication date
01-12-1998
Publisher
Kluwer Academic Publishers
Published in
Biotherapy / Issue 4/1998
Print ISSN: 0921-299X
Electronic ISSN: 1573-8280
DOI
https://doi.org/10.1023/A:1008054111445

Other articles of this Issue 4/1998

Biotherapy 4/1998 Go to the issue

OriginalPaper

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources

OriginalPaper

Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide

OriginalPaper

Low dose Oral Interferon Alpha 2a in HIV-1 Seropositive Patients: A Double-blind, Placebo-controlled Trial

OriginalPaper

Effect of herbal therapy on herpes labialis and herpes genitalis

OriginalPaper

Levamisole and Interleukin-2 for advanced malignancy

OriginalPaper

The use of BRM-activated killer cells in adoptive immunotherapy: A pilot study with nine advanced cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits